Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA warns Juul over marketing practices

The U.S. Food and Drug Administration issued a warning letter to Juul Labs Inc. over the company’s marketing practices for e-cigarettes.

Read More »

J&J liable in Oklahoma opioid epidemic trial

An Oklahoma judge ordered Johnson & Johnson to pay $572.1 million to the state for the company’s part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum substantially less than investors expected, driving up J&J shares.

Read More »

Reckitt Benckiser Settles Indivior Opioid Investigation

Reckitt Benckiser Group agreed to pay $1.4 billion to settle a U.S. investigation into the sales and marketing of Suboxone Film, a product managed by the spinout company Indivior.

Read More »

Consumer/Patient Experience Special Feature: Return on experience

In healthcare, we are fortunate to have access to code that analyzes data and provides us with customer insights. As marketers, we can now understand these individual customers better than ever before. We know what we need and want to do when it comes to reaching them. But what does all that power and possibility do for them?

Read More »

HBA Global presents Virtual Professionals: Visibility & Trajectory in a Virtual Career (Series Purchase – 3 Webinars)

Are you in sales, working out in the field or working remotely or virtually, away from the home office? Then these webinars are for you! Join the HBA for a three-part webinar series that takes on core challenges that virtual workers – both field-based and remote – face in their careers: gaining and improving visibility; career planning; and building relationships with mentors, sponsors and coaches.

Read More »

Teva Pharm to pay Oklahoma $85 million to settle opioid claims

Teva Pharmaceutical agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that the world’s largest generic manufacturer and other drugmakers helped fuel the U.S. opioid epidemic.

Read More »

Gilead Sciences Cuts 150 Sales Jobs

The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.

Read More »

Agenda 2019 Special Feature: Hungry AIs

Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?

Read More »

Medical affairs in the digital age

Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.

Read More »

J&J, U.S. states settle hip implant claims for $120 million

Johnson & Johnson and the company’s DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states over the company’s metal-on-metal hip implants.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom